PPIEL: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: PPIEL

NCBI ID: G728448

PPIEL

Other Name(s): peptidylprolyl isomerase E like pseudogene | FLJ36340 | PPIEL variant 1 | Peptidylprolyl isomerase E like pseudogene, transcript variant 1 | LOC728448 | PPIEP1 | FLJ35287

PPIEL: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), affect millions of people worldwide, causing significant morbidity and economic burden. Chronic inflammation in these diseases can lead to progressive tissue damage, chronic pain, and decreased quality of life. The underlying causes of these diseases are complex and multifactorial, but the involvement of an overactive immune system is often identified. In recent years, the discovery of novel targets for the treatment of inflammatory diseases has promising implications for the development of new therapies. One of these targets is the pseudogene PPIEL (peptidylprolyl isomerase E like), which has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases.

History of PPIEL

PPIEL, also known as PPIEL-like 1, is a gene that encodes a protein with unique catalytic properties. The protein produced by PPIEL is involved in the regulation of inflammation and immune responses. It has been shown to play a critical role in the regulation of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. PPIEL is also involved in the regulation of anti-inflammatory cytokines, such as IL-10. These cytokines are crucial for the regulation of immune and inflammatory responses, and their imbalance is associated with the development of inflammatory diseases.

The discovery of PPIEL

The discovery of PPIEL was made through a screening experiment using a library of human genes. The screening process was designed to identify genes that encode proteins with unique functions, including those involved in inflammation and immune responses. The researchers were looking for genes that encode proteins with structural similarity to known enzymes involved in the regulation of inflammation and immune responses, such as the isomerase enzyme superfamily.

The PPIEL gene was identified through this screening process, and its function was further confirmed through biochemical and genetic studies. PPIEL is a pseudogene, which means that it is a genetic copy of a gene that does not code for a functional protein. Despite this, PPIEL has been shown to have all the features of a functional protein, including a unique catalytic mechanism and a well-conserved catalytic site.

The role of PPIEL in inflammation

PPIEL is involved in the regulation of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines are crucial for the regulation of immune and inflammatory responses. During inflammation, PPIEL catalyzes the conversion of pro-inflammatory cytokines to their active forms. This process is critical for the regulation of inflammation and the immune response.

In addition to its role in the regulation of pro-inflammatory cytokines, PPIEL is also involved in the regulation of anti-inflammatory cytokines, such as IL-10. These cytokines help to counteract the pro-inflammatory effects of other cytokines and play a crucial role in the regulation of immune and inflammatory responses. The balance between pro-inflammatory and anti-inflammatory cytokines is critical for the regulation of inflammation and the immune response.

The potential therapeutic implications of PPIEL

The discovery of PPIEL as a potential drug target and biomarker for the treatment of inflammatory diseases is promising. PPIEL has been shown to play a critical role in the regulation of pro-inflammatory cytokines, making it an attractive target for the development of new therapies. Additionally, its well-conserved catalytic site makes it a promising candidate for small molecule inhibitors.

PPIEL has also been shown to be involved in the regulation of cellular processes that are crucial for the development and maintenance of cancer. The overactive immune system that is associated with the development of cancer is a key example of

Protein Name: Peptidylprolyl Isomerase E Like Pseudogene

The "PPIEL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIEL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets